11 results on '"Jawhara M"'
Search Results
2. Complete Genome Sequence of Cluster J Mycobacteriophage Superphikiman
- Author
-
Jawhara M. Karam, Ashley E. Mathew, Pooja D. Patel, Shika Veera, Nicole E. Cox, Matthew T. McDonald, Bhavya T. Thuremella, Kevin P. W. Smith, Pauline M. Good, Ramnik S. Gill, Niteesha Betini, Katy S. Vieira, Pratik Pradhan, Priyanka Shah, Shelby Jain, Esther J. Han, Mallika Kodavatiganti, Joy L. Little, Karima Rai, Arghyadeep Sarkar, Kevin C. Fitzpatrick, David Bollivar, Esha A. Gajjar, Matthew C. Erlich, Leila M. Haddad, Shivani Patel, Maanasa Natrajan, Justina Toma, Trinh Tran, Ravi K. Tata, Andrew M. Devaney, Clara R. White, Ritu R. Dalia, Vamsee K. Vemulapalli, Catherine E. MacDonald, Nirali Patel, Nishtha Gupta, Brianna M. Wong, Brenna K. Doyle, Andrew D. Jurgielewicz, Dharman Anandarajan, Shivangi D. Bhatt, Bela P. Delvadia, Lavanya S. Aluri, Anjali Ganguly, Arden O. Edgerton, Trevor V. Vidas, Tru A. Walor, Aishwary S. Desai, Gayathri Vijayakumar, Sinja J. Kriete, Andrew S. Jiang, Shu L. Zhao, Andrew Tawfik, Nusrat M. Nishu, Kaustav Patra, Susan M. R. Gurney, Devneet K. Kainth, Josh P. Maret, Swetha Chengalvala, and Sprikena Nako
- Subjects
0301 basic medicine ,Whole genome sequencing ,biology ,Mycobacteriophage ,Computational biology ,biology.organism_classification ,Disease cluster ,Genome ,Bacteriophage ,03 medical and health sciences ,030104 developmental biology ,Transfer RNA ,Viruses ,Genetics ,Molecular Biology ,Gene - Abstract
Mycobacteriophage Superphikiman is a cluster J bacteriophage which was isolated from soil collected in Philadelphia, PA. Superphikiman has a 109,799-bp genome with 239 predicted genes, including 2 tRNA genes.
- Published
- 2018
3. Complete Genome Sequence of Cluster J Mycobacteriophage Superphikiman
- Author
-
Pradhan, Pratik, primary, Nako, Sprikena, additional, Tran, Trinh, additional, Aluri, Lavanya S., additional, Anandarajan, Dharman, additional, Betini, Niteesha, additional, Bhatt, Shivangi D., additional, Chengalvala, Swetha, additional, Cox, Nicole E., additional, Delvadia, Bela P., additional, Desai, Aishwary S., additional, Devaney, Andrew M., additional, Doyle, Brenna K., additional, Edgerton, Arden O., additional, Erlich, Matthew C., additional, Fitzpatrick, Kevin C., additional, Gajjar, Esha A., additional, Ganguly, Anjali, additional, Gill, Ramnik S., additional, Good, Pauline M., additional, Gupta, Nishtha, additional, Haddad, Leila M., additional, Han, Esther J., additional, Jain, Shelby, additional, Jiang, Andrew, additional, Jurgielewicz, Andrew D., additional, Kainth, Devneet K., additional, Karam, Jawhara M., additional, Kodavatiganti, Mallika, additional, Kriete, Sinja J., additional, MacDonald, Catherine E., additional, Maret, Josh P., additional, Mathew, Ashley E., additional, Natrajan, Maanasa, additional, Nishu, Nusrat M., additional, Patel, Nirali, additional, Patel, Pooja D., additional, Patel, Shivani, additional, Patra, Kaustav, additional, Rai, Karima K., additional, Sarkar, Arghyadeep, additional, Shah, Priyanka, additional, Tata, Ravi K., additional, Tawfik, Andrew H., additional, Thuremella, Bhavya T., additional, Toma, Justina, additional, Veera, Shika, additional, Vemulapalli, Vamsee K., additional, Vidas, Trevor V., additional, Vieira, Katy S., additional, Vijayakumar, Gayathri, additional, Walor, Tru A., additional, White, Clara R., additional, Wong, Brianna M., additional, Zhao, Shu L., additional, Bollivar, David W., additional, McDonald, Matthew T., additional, Dalia, Ritu R., additional, Smith, Kevin P. W., additional, Little, Joy L., additional, and Gurney, Susan M. R., additional
- Published
- 2018
- Full Text
- View/download PDF
4. Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study.
- Author
-
Gregersen L, Jessen PD, Lund HW, Overgaard SH, Hikmat Z, Ellingsen T, Kjeldsen J, Pedersen AK, Petersen SR, Jawhara M, Nexøe AB, Bygum A, Hvas CL, Dahlerup JF, Bergenheim FO, Glerup H, Henriksen RH, Guldmann T, Hvid L, Brodersen J, Munk HL, Pedersen N, Saboori S, Nielsen OH, Heitmann BL, Haldorsson TI, Christensen R, and Andersen V
- Abstract
Chronic inflammatory diseases (CIDs) pose a growing healthcare challenge, with a substantial proportion of patients showing inadequate response to biological treatment. There is renewed interest in dietary changes to optimize treatment regimens, with a growing body of evidence suggesting beneficial effects with adherence to a gluten-free diet. This study compared the likelihood of achieving clinical response to biological treatment after 14-16 weeks in patients with CID with high versus low-to-medium gluten intake. Secondary outcomes of interest included changes in disease activity, health-related quality of life and C-reactive protein. The study was a multicentre prospective cohort of 193 participants with a CID diagnosis (i.e. Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis or Psoriasis) who initiated biological treatment between 2017 and 2020. Participants were stratified based on their habitual gluten intake: the upper 33.3% (high gluten intake) and the remaining 66.6% (low-to-medium gluten intake). The proportion of patients achieving clinical response to biological treatment after 14-16 weeks was compared using logistic regression models. The median gluten intake differed significantly between groups (12.5 g/day vs. 5.9 g/day, standardized mean difference = 1.399). In total, 108 (56%) achieved clinical response to treatment, with no difference between 35 (55%) in the high gluten group and 73 (57%) in the medium-to-low gluten group (OR = 0.96 [0.51-1.79], p = 0.897). No differences were found with secondary outcomes. In conclusion, this study found no association between gluten intake and response to biological treatment in patients with CID., (© 2024 The Author(s). Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study.
- Author
-
Larsen MGR, Overgaard SH, Petersen SR, Møllegaard KM, Munk HL, Nexøe AB, Glerup H, Guldmann T, Pedersen N, Saboori S, Dahlerup JF, Hvas CL, Andersen KW, Jawhara M, Haagen Nielsen O, Bergenheim FO, Brodersen JB, Bygum A, Ellingsen T, Kjeldsen J, Christensen R, and Andersen V
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Prospective Studies, Treatment Outcome, Psoriasis drug therapy, Colitis, Ulcerative drug therapy, Chronic Disease, Crohn Disease drug therapy, Cohort Studies, Arthritis, Psoriatic drug therapy, Aged, Inflammation, Smoking adverse effects, Biological Products therapeutic use, Arthritis, Rheumatoid drug therapy
- Abstract
The prevalence and disease burden of chronic inflammatory diseases (CIDs) are predicted to rise. Patients are commonly treated with biological agents, but the individual treatment responses vary, warranting further research into optimizing treatment strategies. This study aimed to compare the clinical treatment responses in patients with CIDs initiating biologic therapy based on smoking status, a notorious risk factor in CIDs. In this multicentre cohort study including 233 patients with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or psoriasis initiating biologic therapy, we compared treatment response rates after 14 to 16 weeks and secondary outcomes between smokers and non-smokers. We evaluated the contrast between groups using logistic regression models: (i) a "crude" model, only adjusted for the CID type, and (ii) an adjusted model (including sex and age). Among the 205 patients eligible for this study, 53 (26%) were smokers. The treatment response rate among smokers (n = 23 [43%]) was lower compared to the non-smoking CID population (n = 92 [61%]), corresponding to a "crude" OR of 0.51 (95% CI: [0.26;1.01]) while adjusting for sex and age resulted in consistent findings: 0.51 [0.26;1.02]. The contrast was apparently most prominent among the 38 RA patients, with significantly lower treatment response rates for smokers in both the "crude" and adjusted models (adjusted OR 0.13, [0.02;0.81]). Despite a significant risk of residual confounding, patients with CIDs (rheumatoid arthritis in particular) should be informed that smoking probably lowers the odds of responding sufficiently to biological therapy. Registration: Clinical.Trials.gov NCT03173144., (© 2024 The Author(s). Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.)
- Published
- 2024
- Full Text
- View/download PDF
6. Robot-assisted versus laparoscopic short- and long-term outcomes in complete mesocolic excision for right-sided colonic cancer: a systematic review and meta-analysis.
- Author
-
Cuk P, Jawhara M, Al-Najami I, Helligsø P, Pedersen AK, and Ellebæk MB
- Subjects
- Humans, Treatment Outcome, Colectomy adverse effects, Colectomy methods, Lymph Node Excision methods, Robotics, Laparoscopy methods, Colonic Neoplasms pathology, Mesocolon surgery, Mesocolon pathology
- Abstract
Background: Complete mesocolic excision (CME) surgery is increasingly implemented for the resection of right-sided colonic cancer, possibly resulting in improved 5-year overall and disease-free survival compared to non-CME surgery. However, it is not clear what surgical platform should be used. The aim of this study was to compare the following outcomes between robot-assisted and laparoscopic CME-surgery for right-sided colonic cancer: (i) short-term clinical outcomes, (ii) pathological specimen quality, and (iii) long-term oncological outcomes., Methods: Medline, Embase, and Cochrane Database of Systematic Reviews were searched from inception until August 2021. Pooled proportions were calculated by applying the inverse variance method. Heterogeneity was explored by I-square and supplemented by sensitivity- and meta-regression analyses. The risk of bias was evaluated by either MINORS or Cochrane's risk-of-bias tool (RoB 2)., Results: Fifty-five studies with 5.357 patients (740 robot-assisted and 4617 laparoscopic) were included in the meta-analysis. Overall postoperative morbidity was 17% [95% CI (14-20%)] in the robot-assisted group and 13% [95%CI (12-13%)] in the laparoscopic group. Robot-assisted CME was associated with a shorter hospital stay, lower intraoperative blood loss, a higher amount of harvested lymph nodes, and better 3-year oerall and disease-free survival. MINORS and RoB2 indicated a serious risk of bias across studies included., Conclusions: This review which includes predominantly non-randomized studies suggests a possible advantage of the robot-assisted CME compared with a laparoscopic technique for several short-term outcomes., (© 2022. Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
7. Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study.
- Author
-
Overgaard SH, Sørensen SB, Munk HL, Nexøe AB, Glerup H, Henriksen RH, Guldmann T, Pedersen N, Saboori S, Hvid L, Dahlerup JF, Hvas CL, Jawhara M, Andersen KW, Pedersen AK, Nielsen OH, Bergenheim F, Brodersen JB, Heitmann BL, Halldorsson TI, Holmskov U, Bygum A, Christensen R, Kjeldsen J, Ellingsen T, and Andersen V
- Abstract
Background: Biologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies., Objective: To investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID., Methods: In this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14-16 weeks of treatment., Results: Of the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group ( N = 64), 41 (64%) patients responded to treatment compared to 73 (56%) in the LFHM group ( N = 129), but the difference was not statistically significant (OR: 1.48, 0.72-3.05). For RA patients however, HFLM diet was associated with a more likely clinical response (82% vs. 35%; OR: 9.84, 1.35-71.56)., Conclusion: Habitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial., Trial Registration: (clinicaltrials.gov), identifier [NCT03173144]., Competing Interests: Author CH has received speaker fee from Takeda Pharma and Tillotts Pharma (unrelated to the present work). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Overgaard, Sørensen, Munk, Nexøe, Glerup, Henriksen, Guldmann, Pedersen, Saboori, Hvid, Dahlerup, Hvas, Jawhara, Andersen, Pedersen, Nielsen, Bergenheim, Brodersen, Heitmann, Halldorsson, Holmskov, Bygum, Christensen, Kjeldsen, Ellingsen and Andersen.)
- Published
- 2022
- Full Text
- View/download PDF
8. The Relation between Red Meat and Whole-Grain Intake and the Colonic Mucosal Barrier: A Cross-Sectional Study.
- Author
-
Jawhara M, Sørensen SB, Heitmann BL, Halldórsson ÞI, Pedersen AK, and Andersen V
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Colon microbiology, Colon pathology, Colonoscopy, Cross-Sectional Studies, Denmark, Diet Surveys, Female, Humans, In Situ Hybridization, Fluorescence, Intestinal Mucosa microbiology, Intestinal Mucosa pathology, Male, Microbiota, Middle Aged, Mucin-2 genetics, Mucin-2 metabolism, Mucus metabolism, Mucus microbiology, Colon metabolism, Diet methods, Intestinal Mucosa metabolism, Red Meat, Whole Grains
- Abstract
The Colonic Mucosal Barrier (CMB) is the site of interaction between the human body and the colonic microbiota. The mucus is the outer part of the CMB and is considered as the front-line defense of the colon. It separates the host epithelial lining from the colonic content, and it has previously been linked to health and diseases. In this study, we assessed the relationship between red meat and whole-grain intake and (1) the thickness of the colonic mucus (2) the expression of the predominant mucin gene in the human colon ( MUC2 ). Patients referred to colonoscopy at the University Hospital of Southern Denmark- Sonderjylland were enrolled between June 2017 and December 2018, and lifestyle data was collected in a cross-sectional study design. Colonic biopsies, blood, urine, and fecal samples were collected. The colonic mucus and bacteria were visualized by immunostaining and fluorescence in situ hybridization techniques. We found a thinner mucus was associated with high red meat intake. Similarly, the results suggested a thinner mucus was associated with high whole-grain intake, albeit to a lesser extent than red meat. This is the first study assessing the association between red meat and whole-grain intake and the colonic mucus in humans. This study is approved by the Danish Ethics Committee (S-20160124) and the Danish Data Protecting Agency (2008-58-035). A study protocol was registered at clinical trials.gov under NCT04235348., Competing Interests: The authors declare no conflicts of interest. The funders had no role in the study design, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2020
- Full Text
- View/download PDF
9. Biomarkers of Whole-Grain and Cereal-Fiber Intake in Human Studies: A Systematic Review of the Available Evidence and Perspectives.
- Author
-
Jawhara M, Sørensen SB, Heitmann BL, and Andersen V
- Subjects
- Adult, Aged, Avena, Benzoxazines urine, Biomarkers blood, Biomarkers urine, Diet, Dietary Fiber administration & dosage, Feeding Behavior, Female, Hordeum, Humans, Male, Middle Aged, Reproducibility of Results, Resorcinols urine, Secale, Triticum, Benzoxazines blood, Edible Grain, Resorcinols blood, Saponins urine, Whole Grains
- Abstract
High whole-grain consumption is related to better health outcomes. The specific physiological effect of these compounds is still unrevealed, partly because the accurate estimation of the intake of whole grains from dietary assessments is difficult and prone to bias, due to the complexity of the estimation of the intake by the consumer. A biomarker of whole-grain intake and type of whole-grain intake would be useful for quantifying the exposure to whole-grain intake. In this review, we aim to review the evidence on the potential biomarkers for whole-grain intake in the literature. We conducted a systematic search in Medline, Embase, Web of Science, and the Cochrane database. In total, 39 papers met the inclusion criteria following the PRISMA guidelines and were included. The relative validity, responsiveness, and reproducibility of these markers were assessed for short-, medium-, and long-term exposure as important criteria for the potential use of these biomarkers from a clinical and research perspective. We found three major groups of biomarkers: (1) alkylresorcinol, as well as its homologs and metabolites, assessed in plasma, adipose tissue biopsies, erythrocyte membranes, and urine; (2) avenacosides, assessed in urine samples; and (3) benzoxazinoid-derived phenylacetamide sulfates, assessed in blood and urine samples. The reviewed biomarkers may be used for improved assessment of associations between whole-grain intake and health outcomes., Competing Interests: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2019
- Full Text
- View/download PDF
10. Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine.
- Author
-
Christensen R, Heitmann BL, Andersen KW, Nielsen OH, Sørensen SB, Jawhara M, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Bennike TB, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Boye M, Werner L, Nielsen CL, Munk HL, Nexøe AB, Ellingsen T, Holmskov U, Kjeldsen J, and Andersen V
- Subjects
- Chronic Disease, Diet, Humans, Inflammatory Bowel Diseases therapy, Life Style, Patient Reported Outcome Measures, Precision Medicine, Prognosis, Prospective Studies, Quality of Life, Research Design, Rheumatic Diseases therapy, Skin Diseases therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors, Uveitis therapy, Dietary Fiber administration & dosage, Inflammation, Meat Products adverse effects, Red Meat adverse effects
- Abstract
Introduction: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine. The primary outcome of this multidisciplinary collaborative study will be to identify dietary lifestyle factors that support optimal treatment outcomes., Methods and Analysis: This prospective cohort study will enrol 320 patients with CID who are prescribed a TNFi between June 2017 and March 2019. Included among the patients with CID will be patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatic disorders (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin diseases (psoriasis, hidradenitis suppurativa) and non-infectious uveitis. At baseline (pretreatment), patient characteristics will be assessed using patient-reported outcome measures, clinical assessments of disease activity, quality of life and lifestyle, in addition to registry data on comorbidity and concomitant medication(s). In accordance with current Danish standards, follow-up will be conducted 14-16 weeks after treatment initiation. For each disease, evaluation of successful treatment response will be based on established primary and secondary endpoints, including disease-specific core outcome sets. The major outcome of the analyses will be to detect variability in treatment effectiveness between patients with different lifestyle characteristics., Ethics and Dissemination: The principle goal of this project is to improve the quality of life of patients suffering from CID by providing evidence to support dietary and other lifestyle recommendations that may improve clinical outcomes. The study is approved by the Ethics Committee (S-20160124) and the Danish Data Protecting Agency (2008-58-035). Study findings will be disseminated through peer-reviewed journals, patient associations and presentations at international conferences., Trial Registration Number: NCT03173144; Pre-results., Competing Interests: Competing interests: All authors declare no conflict of interest. However, the following authors declare: B. Heitmann has received funding from ‘MatPrat’, the information office for Norwegian egg and meat; L. Hvid is on the advisory board for Abbvie A/S; J. Fallingborg is on the advisory boards for AbbVie A/S, MSD Denmark, Takeda Pharma A/S, and Ferring Pharmaceuticals A/S; V. Andersen receives compensation for consultancy and for being a member of the advisory board for MSD Denmark (Merck) and Janssen A/S. The funding sponsors had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2018
- Full Text
- View/download PDF
11. A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
- Author
-
Andersen V, Holmskov U, Sørensen SB, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Nielsen OH, Christensen R, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Heitmann B, Boye M, Nielsen CL, Werner L, Kjeldsen J, and Ellingsen T
- Subjects
- Biomarkers blood, Body Mass Index, Denmark, Diet, Dietary Fats administration & dosage, Dietary Fiber administration & dosage, Dietary Proteins administration & dosage, Exercise, Fatty Acids, Unsaturated administration & dosage, Female, Follow-Up Studies, Gene-Environment Interaction, Humans, Intestinal Mucosa metabolism, Male, Meat, Micronutrients administration & dosage, Prospective Studies, Smoking therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases diet therapy, Inflammatory Bowel Diseases drug therapy, Life Style, Precision Medicine
- Abstract
Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.